Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Biopsy-proven\* relapsed or refractory lymphoma, including the following:
• •* Aggressive lymphoma (closed to accrual as of 2/7/08 except for diffuse large B cell lymphoma, grade III follicular lymphoma, or transformed lymphoma)
• •* Transformed lymphoma
• •* Diffuse large B-cell lymphoma
• •* Mantle cell lymphoma
• •* Grade 3 follicular lymphoma
• •* Precursor B-cell lymphoblastic leukemia/lymphoma
• •* Mediastinal (thymic) large B-cell lymphoma
• •* Burkitt's lymphoma/leukemia
• •* Precursor T-cell lymphoblastic leukemia/lymphoma
• •* Primary cutaneous anaplastic large cell lymphoma
• •* Primary systemic type anaplastic large cell lymphoma
• •* Indolent lymphoma (closed to accrual as of 8/18/08)
• •* Small lymphocytic lymphoma/chronic lymphocytic leukemia
• •* Grade 1 or 2 follicular lymphoma
• •* Extranodal marginal zone B-cell lymphoma of MALT type
• •* Nodal marginal zone B-cell lymphoma
• •* Splenic marginal zone B-cell lymphoma
• •* Uncommon lymphoma (closed to accrual as of 9/2/08)
• •* Unspecified peripheral T-cell lymphoma
• •* Anaplastic large cell lymphoma (T and null cell type)
• •* Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)
• •* Central Nervous System (CNS) lymphoma
• •* Post-transplant lymphoproliferative disorder
• •* Mycosis fungoides/Sezary syndrome
• •* Hodgkin's lymphoma
• •* Primary effusion lymphoma
• •* Blastic Natural Killer(NK)-cell lymphoma
• •* Adult T-cell leukemia/lymphoma
• •* Nasal type extranodal NK/T-cell lymphoma
• •* Enteropathy type T-cell lymphoma
• •* Hepatosplenic T-cell lymphoma
• •* Subcutaneous panniculitis-like T-cell lymphoma
• •* Angioimmunoblastic T-cell lymphoma
• •NOTE: \*Biopsies performed \< 6 months prior to study entry are allowed; biopsy-proven CNS lymphoma (at any time) does not require a re-biopsy in order to be eligible for this study
• •Previously treated disease
• •* Patients with aggressive lymphoma (closed to accrual as of 8/24/07) OR Hodgkin's lymphoma must have received or be ineligible for potentially curative therapy, including stem cell transplantation
• •Measurable disease\*\* by CT scan or MRI, defined by 1 of the following:
• •* At least 1 unidimensionally measurable lesion \> 2 cm in diameter
• •* Skin lesions may be used if they meet this criterion and are photographed with a ruler
• •* More than 5,000/mm³ tumor cells in the blood
• •NOTE: \*\*For patients with lymphoplasmacytic lymphoma without measurable lymphadenopathy, measurable disease may be defined by bone marrow lymphoplasmacytosis with \> 10% lymphoplasmacytic cells or aggregates, sheets, lymphocytes, plasma cells, or lymphoplasmacytic cells on bone marrow biopsy AND quantitative Immunoglobulin M(IgM) monoclonal protein \> 1,000 mg/dL
• •PATIENT CHARACTERISTICS:
• •Eastern Cooperative Oncology Group(ECOG) performance status 0-2
• •Life expectancy \> 3 months
• •Absolute neutrophil count ≥ 1,000/mm³
• •Platelet count ≥ 75,000/mm³
• •Hemoglobin ≥ 8 g/dL
• •Total bilirubin ≤ 2 times upper limit of normal (ULN) OR direct bilirubin ≤ 1.5 times ULN
• •aspartate aminotransferase(AST) ≤ 3 times ULN (5 times ULN if liver involvement is present)
• •Creatinine ≤ 2 times ULN
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •Willing to provide blood samples and portion of bone marrow aspirate and biopsy during study participation
• •Able to swallow intact study medication tablets
• •No other life-threatening illness (unrelated to tumor)
• •No serious non-malignant disease (e.g., active infection or other condition) that, in the opinion of the investigator, would preclude study participation
• •No other active malignancy requiring treatment or that would preclude study participation
• •No known HIV positivity
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •At least 3 weeks since prior myelosuppressive chemotherapy or biologic therapy (unless the patient has recovered from the nadir of the previous treatment)
• •More than 3 weeks since prior radiotherapy (unless the acute side effects associated with therapy are resolved)
• •Concurrent stable (i.e., not increased within the past month) chronic doses of corticosteroids, with a maximum dose of 20 mg of prednisone per day, is allowed if prescribed for disorders other than lymphoma (e.g., rheumatoid arthritis, polymyalgia rheumatica, adrenal insufficiency, or asthma)
• •* Non-escalating doses of steroids at the lowest possible dosing level are allowed for CNS lymphoma
• •No other concurrent investigational ancillary therapy
• •No other concurrent chemotherapy, immunotherapy, or radiotherapy
• •No concurrent participation in any other clinical trial involving a pharmacologic agent (e.g., drugs, biologics, immunotherapy, or gene therapy) for symptom control or therapeutic intent